Depression:
the projected leading cause of disability globally by 2030.

The annual economic burden in the USA alone is now $210 billion dollars. Depression has devastating effects on individuals, families and communities.

Current poor treatment response.

Data shows 30 – 50% of depressed patients do not respond to their first medication. Antidepressant remission rates are lower than those for response at 37.5%. Our product provides hope to improve these numbers

Up to 50% of depressed patients do not respond to their first medication

Introducing second generation pharma-cogenetics.

Our novel technology uses trade secrets and multiple genetic polymorphisms to guide antidepressant choice and dosing.

Antidepressant remission rates are lower than those for response at 37.5%

Our trade secret technology:
the keys to the blood brain barrier.

Our product is the first-in-case using this technology. Our system analyses two key pharmacokinetic steps governing antidepressant central nervous system (CNS) bioavailability − hepatic metabolism enzyme system (CYP450 & UGT1A1) and the active efflux transporters (ABC transporters) at the Blood Brain Barrier.
watch the video

Strong evidence:
RCT shows gene guidance doubles remission.

We have published the world's first positive Randomised Controlled Trial (RCT) and found a remission rate of 72% for genetically guided dosing versus 28% for genetically unguided dosing over twelve weeks. Our number needed to genotype was 3, to produce an additional remission. This equates to level 1b evidence (Oxford System for Evidence-Based Medicine). We have completed a tenure-track academic-led concordance study — publication due mid-2016.

Gene Guidance remission rate %

Strategically designed to scale: globally and rapidly.

We leverage cloud based IT systems and regional exclusivity deals with labs around the world. Our simple approach allows patients to send their saliva sample, have it quickly analysed and details sent to their doctor. Our aim is to strengthen the doctor-patient relationship with easy to understand genetic information.

Growth area in depression pharmaco-genetics.

Over 100 000 similar tests were ordered last year in the USA. Competitor valuations in hundreds of millions. We believe we have a competitive advantage over our competitors with evidence and scalability.